Unlocking the Potential of Chemotherapy

At Sitka Biopharma, we are focused on transforming chemotherapies to further benefit patients by enhancing efficacy and improving tolerability. Utilizing our breakthrough polymeric nanoparticle platform technology, we are able to improve drug absorption of difficult-to-penetrate tissues, thereby enhancing treatment benefit.

With our lead candidate (STK-01) demonstrating preclinical proof-of-concept for bladder cancer, we continue to push towards our goal of developing the first front-line chemotherapy for intermediate- to high-risk bladder cancer patients.